Immix Biopharma, Inc. (IMMX) stock
IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.04−0.07 (-0.98%)
Close on Nov 19, 2026Market cap $503.64MP/E –Yield –
Immix Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Immix Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$39.09M. For fiscal 2025 it was -$24.66M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.66M | – |
| FY2024 | Dec 31, 2024 | -$15.77M | – |
| FY2023 | Dec 31, 2023 | -$11.42M | – |
| FY2021 | Dec 31, 2021 | -$1.59M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -$50.76K | – |
| Q2 FY2021 | Jun 30, 2021 | -$158.01K | – |
| Q1 FY2021 | Mar 31, 2021 | -$267.25K | – |
See a number that looks wrong?